Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Datamonitor Reports | Stakeholder Opinions: Systemic Lupus Erythematosus - Market set to enter era of biologic therapies

Stakeholder Opinions: Systemic Lupus Erythematosus - Market set to enter era of biologic therapies

SLE is a chronic, life-long and potentially fatal autoimmune disease characterized by multiple system distress and unpredictable flares. Therapy is largely off-label and a huge demand exists for new SLE therapies because of the potential for serious side effects from drugs currently used in the management of the disease.

Assessment of patient size across the seven major and additional emerging markets, including split by sex and race where available.

Commercial and clinical assessment of the therapies in the developmental pipeline.

Opinion of the market potential from a range of physicians involved in SLE treatment and research.

An update of the challenges facing the design of clinical trials

The SLE market will enter an era of targeted therapies thanks to greater understanding of disease mechanisms. Rituxan/MabThera (rituximab) is the most advanced pipeline candidate and will be the first product approved in the last 40 years. It is already used off-label in severe, refractory patients, with maximum estimated sales $650m.

Caution must be maintained as products for SLE have been prone to failure, as evidenced by La Jolla's Riquent, Genelabs's Prestara and Apreva's CellCept. Companies must learn from past mistakes by improving SLE clinical trial design and communicating fully with regulatory agencies.

The SLE patient population in the seven major markets is estimated to be 430,000 in 2008. However, the combined SLE patient population in Mexico, China and India could be a minimum of 0.9 billion in 2008, suggesting pharmaceutical companies should seek product approval in emerging markets.

Understand the key opportunities and threats in the SLE market

Assess the commercial potential of the products in the late-stage pipeline

Gain insight into opinion leaders' thoughts on the challenges facing the SLE market

Publication: 39508
Library Code: DMHC2387
Type: Report
Format: PDF & SlidePack
Pages: 108

Table of Contents
Price: $3,800.00 / €2,516.74

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions